Revance Therapeutics, Inc.

Form 4

February 18, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

may continue. See Instruction

1(b).

(Last)

(Print or Type Responses)

1. Name and Address of Reporting Person * 2. Issuer Name and Ticker or Trading Ruegg Curtis Symbol

Revance Therapeutics, Inc. [RVNC]

3. Date of Earliest Transaction

(Month/Day/Year) 02/17/2015

C/O REVANCE THERAPEUTICS. INC., 7555 GATEWAY

(Middle)

(First)

BOULEVARD

NEWARK, CA 94560

(Street) 4. If Amendment, Date Original

Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

OMB APPROVAL

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

Director 10% Owner Other (specify _X__ Officer (give title below)

EVP, Technical Operations

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
--------	---------	-------	--

		Table	1 - 14011-10	envauve	occuri	ues Acq	juii cu, Disposcu o	i, oi benenciai	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year)		4. Securities Acquired n(A) or Disposed of (D)			5. Amount of Securities Beneficially	6. Ownership Form: Direct (D) or	7. Nature of Indirect Beneficial
		(Instr. 8)	(Instr. 3, 4 and 5)			Owned Following Reported	Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
			Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		
Common Stock	02/17/2015		M	170	A	\$ 2.55	19,507	D	
Common Stock	02/17/2015		M	830	A	\$ 6.6	20,337	D	
Common Stock	02/17/2015		S <u>(1)</u>	170	D	\$ 16.8	20,167	D	
Common Stock	02/17/2015		S(1)	830	D	\$ 16.8	19,337	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	orof Deri Secu Acq (A) Disp of (I	osed (a) (a) (b) (c) (c) (c) (c) (c) (c) (c) (c) (c) (c	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Pri Deriv Secur (Instr
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 2.55	02/17/2015		M		170	(2)	04/29/2018	Common Stock	170	\$
Stock Option (Right to Buy)	\$ 6.6	02/17/2015		M		830	(3)	05/15/2016	Common Stock	830	\$

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Ruegg Curtis C/O REVANCE THERAPEUTICS, INC. 7555 GATEWAY BOULEVARD NEWARK, CA 94560

EVP, Technical Operations

Signatures

/s/ Gordon Ho, Attorney-in-fact 02/18/2015

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Reporting Owners 2

Edgar Filing: Revance Therapeutics, Inc. - Form 4

- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2014.
- (2) The Option is fully vested as of January 1, 2012.
- (3) The Option is fully vested as of May 16, 2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.